In vitro cleavage of Gazdar murine sarcoma virus Pr65~ ~, which has all of the antigenic determinants of Moloney murine leukaemia virus Pr65 gag, i.e. p15, p12, p30 and pl0, by the Moloney murine leukaemia virus proteolytic activity yielded a p30 whose partial NH2-terminal sequence was identical to Moloney murine leukaemia virus. Both [3H]leucine-labelled and unlabelled Pr659ag were used to generate the cleaved p30.
. Virus was stored in STE buffer. Protein concentration was determined by the Bio-Rad protein assay. After incubation, the reaction mixtures were analysed by SDS-PAGE (Laemmli, 1970) To study the in vitro cleavage site, we have determined the amino-terminal sequence of p30 generated upon cleavage of GzMSV Pr65 gag by the MoMuLV proteolytic factor. MoMuLV which served as the source of the proteolytic factor was purified from culture fluids of MJD-54 cells and GzMSV, the substrate, was purified from culture fluids of HTG-2 cells. Each preparation was initially checked for proteolytic activity as follows: a sample of virus was disrupted by addition of 2~ NP40 and 0.01 M-dithiothreitol (DTT), the lysate was either incubated at 4 °C (control, no activity) or 22 °C (activity) for 20 h and then analysed by SDS-PAGE. Fig. 1 shows what happened when MoMuLV was incubated under these experimental conditions. The small amount of Pr65g ag present in MoMuLV preparations remained intact when incubation was at 4 °C (lane a); however, both Pr65 gag and the intermediate cleavage product Pr40gag disappeared when the NP40 lysate was incubated at 22 °C (lane b). Further, if GzMSV was incubated alone under these conditions, Pr65 gag remained uncleaved regardless of whether the NP40 extract was incubated at either 4 °C or 22 °C (lane c). This suggested the absence of an active proteolytic factor in GzMSV preparations, and thus we could set up our in vitro cleavage system with GzMSV Pr65 gag and MoMuLV as described above. . The PTH derivatives of amino acids were identified by HPLC on a phenyl alkyl column (Henderson et aL, 1980) . We found, as expected, that when increasing concentrations of the MoMuLV NP40 extracts were incubated with a constant amount of GzMSV, there was a correlative increased cleavage of Pr65 ga9 to Pr40 g~9 to p30 (Fig. 2) . Because of the addition of a relatively large amount of MoMuLV protein to the mixture, the p30 seen in Fig. 2 (d) was obtained both from the cleaved GzMSV, as well as from the added MoMuLV extract. In order to obtain p30 that was derived almost solely from GzMSV Pr65 gag, so that we could use it to identify the NH2 terminus, we used two approaches.
First, since it was known that the amino-terminal sequence of MoMuLV p30 had leucine at positions 2 and 10 (Oroszlan & Gilden, 1980) , we decided to use [3H]leucine-labelled GzMSV Pr65~ ~9 in the proteolytic assay mixture, then to purify p30 and determine where [3H]leucine was located. If cleavage occurred with fidelity then it should be present at positions 2 and 10 of p30 cleaved in ~,itro. If not, [3 H]leucine would be found elsewhere. [3 H]Leucine-labelled GzMSV was prepared from labelled HTG-2 cells as follows. Cells were grown to near confluency in four 850 cm roller bottles, culture fluids were removed and the cells washed twice with leucine-free MEM. Then cells were labelled using 12.5 ml ofleucine-free MEM, 10~ dialysed calf serum and 0.1 mCi/ml (sp. act. 40 Ci/mmol)of L-[4,5 -3 H]leucine (ICN) followed by incubation at 37 °C for 24 h. Virus was precipitated by centrifugation at 40000 r.p.m, for 60 min at 4 °C using a Beckman type 42.1 rotor, the pellet was resuspended with unlabelled GzMSV which had been previously purified from HTG-2 cell culture fluids, and the mixture was repurified on a 20 to 50~ sucrose gradient. Then, labelled virus (0.625 mg [3H]leucine-labelled GzMSV, containing 106 c.p.m.) was mixed with unlabelled MoMuLV in a 1:7 ratio. After NP40 disruption and incubation under our protease assay conditions, the resulting protein mixture was separated by SDS-PAGE (12.5~o acrylamide). The slab gels were sliced into 80 pieces (1-5 mm thick), each fraction was crushed and protein eluted into STE (0.13 M-NaC1, 0.01 M-Tris-HC1, 0.001 M-EDTA, pH 8-5) with SDS (0.1 ~). The peak of pH]leucine was determined by counting the radioactivity in each fraction from the gel, and as expected it was located in the vicinity of the p30 position. This was further analysed by running a 12.5 ~ SDS-polyacrylamide gel of the peak material, followed by fluorography (Bonner & Laskey, 1974 (e) The material of (d) was loaded onto a phosphocellulose column (1-5 x 10 cm), eluted with 1 M-KC1, and the eluate was dialysed against STE. Then the dialysate was concentrated to 1 ml with Sephadex G-200. Finally, the concentrated material was passed through a Sephadex G-75 column, the p30 peak fractions were collected and again concentrated about 10-fold by use of Sephadex G-200, prior to SDS-PAGE.
used for liquid scintillation counting in order to determine the radioactivity in each cycle. Positive identification and quantification of tritiated phenylthiohydantoin (PTH) leucine was achieved by analysing each residue on a high-performance liquid chromatography (HPLC) column. Fractions eluting at the appropriate retention times (as determined with P T H -l e u c i n e standard) were collected, lyophilized and counted for radioactivity. The results are shown in Table 1 , column A. It is clear that [3H] leucine was present at positions 2 a n d 10.
The second approach we used was to isolate G z M S V p30 from an in vitro cleavage reaction between unlabelled G z M S V Pr65gag and the M o M u L V proteolytic factor which had been partially purified from 50 mg of M o M u L V by phosphocellulose column chromatography. This proteolytic activity had only a minor a m o u n t of c o n t a m i n a t i n g p30 ( < 5 ~ total staining, in arbitrary Coomassie Brilliant Blue units; Fig. 3a) relative to the added G z M S V Pr65 gao ( 1 0 0~ total staining; Fig. 3b ). Two mg of the H T G virus (1 ml) was thus mixed with 80 ~tg of the protease active fraction (2 ml), incubated at 2 2°C for 16 h in 0.02M-PIPES, 1 0 m M -D T T (pH 7.2), and the product run on an SDS gel. As seen in Fig 3 (c) , Pr65 oag was p r e d o m i n a n t l y cleaved into a large a m o u n t of p30 and some other lower mol. wt. products. In order to remove Pr27 gag, p 15 and other hydrophobic proteins, a partial purification of p30 was u n d e r t a k e n which involved solubilization of the mixture with 6 M-guanidine-HCl, followed by dialysis against 0-01 M-BES (pH 6.5) and 10mM-DTT at 4°C for 40 h, with three changes of buffer, centrifugation at 10000 r.p.m, for l0 min at 4 °C in a Beckman J-21 centrifuge (lane d (Oroszlan & Gilden, 1980) . Further, we note that with alanine in position 4, it differs from p30 of RMuLV which has leucine in position 4. Taken together, the results of columns A and B indicate that the proteolytic factor from purified MoMuLV accurately cleaves GzMSV Pr65 gag in vitro, and further lend support to the hypothesis that this factor is a 'protease' which acts in vivo to cleave Pr65 ~ag during the final stages of retrovirus maturation.
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